| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H28N2O4 |
| Molecular Weight | 348.4366 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1
InChI
InChIKey=SMTZFNFIKUPEJC-UHFFFAOYSA-N
InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)
| Molecular Formula | C19H28N2O4 |
| Molecular Weight | 348.4366 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Roxatidine is an histamine H2-receptor antagonist. Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H2-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action. Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome also it can be used as a premedication before anaesthesia. Roxatidine possessed a robust estrogenic activity.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Peptic ulcer: 150 mg at bedtime or 75 mg bid daily for 4-6 weeks. Maintenance: 75 mg at bedtime.
Gastro-oesophageal reflux disease: 75 mg bid or 150 mg at bedtime for 6-8 weeks.
Gastritis: 75 mg once daily in the evening.
Zollinger-Ellison syndrome: 75 mg bid.
Premedication before anaesthesia: 75 mg in the evening on the day before surgery and repeated 2 hours before induction of anaesthesia. Alternatively, 150 mg once on the night before surgery.
Intravenous
Upper gastrointestinal haemorrhage: 75 mg bid via slow injection or infusion.
Route of Administration:
Other
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 1 of 1 entries
